Display options
Share it on

AIDS Res Treat. 2014;2014:867827. doi: 10.1155/2014/867827. Epub 2014 Aug 06.

Determinants of Mortality among Adult HIV-Infected Patients on Antiretroviral Therapy in a Rural Hospital in Southeastern Nigeria: A 5-Year Cohort Study.

AIDS research and treatment

Kelechi N Eguzo, Adegboyega K Lawal, Cynthia E Eseigbe, Chisara C Umezurike

Affiliations

  1. School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada S7N 5E5 ; Department of Obstetrics and Gynecology, Nigerian Christian Hospital, Aba, Abia State 450001, Nigeria.
  2. School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada S7N 5E5.
  3. Department of Laboratory Services, Nigerian Christian Hospital, Aba, Abia State 450001, Nigeria.
  4. Department of Obstetrics and Gynecology, Nigerian Christian Hospital, Aba, Abia State 450001, Nigeria.

PMID: 25165579 PMCID: PMC4140117 DOI: 10.1155/2014/867827

Abstract

Background. Study examined the determinants of mortality among adult HIV patients in a rural, tertiary hospital in southeastern Nigeria, comparing mortality among various ART regimens. Methods. Retrospective cohort study of 1069 patients on ART between August 2008 and October 2013. Baseline CD4 counts, age, gender, and ART regimen were considered in this study. Kaplan-Meier method was used to estimate survival and Cox proportional hazards models to identify multivariate predictors of mortality. Median follow-up period was 24 months (IQR 6-45). Results. 78 (7.3%) patients died with 15.6% lost to followup. Significant independent predictors of mortality include age (>45), sex (male > female), baseline CD4 stage (<200), and ART combination. Adjusted mortality hazard was 3 times higher among patients with CD4 count <200 cells/μL than those with counts >500 (95% CI 1.69-13.59). Patients on Truvada-based first-line regimens were 88% more likely to die than those on Combivir-based first line (95% CI 1.05-3.36), especially those with CD4 count <200 cells/μL. Conclusion. Study showed lower mortality than most studies in Nigeria and Africa, with mortality higher among males and patients with CD4 count <200. Further studies are recommended to further compare treatment outcomes between Combivir- and Truvada-based regimens in resource-limited settings using clinical indicators.

References

  1. Glob Health Action. 2010 Oct 29;3: - PubMed
  2. Pathog Glob Health. 2012 Mar;106(1):46-54 - PubMed
  3. AIDS. 2005 Dec 2;19(18):2141-8 - PubMed
  4. AIDS Res Treat. 2012;2012:940580 - PubMed
  5. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD006517 - PubMed
  6. J AIDS Clin Res. 2013 Jun 29;Suppl 3: - PubMed
  7. Expert Opin Pharmacother. 2006 Aug;7(12):1541-54 - PubMed
  8. BMC Infect Dis. 2008 Apr 22;8:52 - PubMed
  9. PLoS One. 2013 May 14;8(5):e64459 - PubMed
  10. AIDS. 2011 Jan 14;25(2):211-20 - PubMed

Publication Types